Back to Search Start Over

Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis

Authors :
Bertholet-Thomas, Aurélia
Guittet, Catherine
Manso-Silván, Maria A.
Joukoff, Sophie
Navas-Serrano, Victor
Baudouin, Véronique
Cailliez, Mathilde
Source :
Pediatric Nephrology. July, 2021, Vol. 36 Issue 7, p1765, 10 p.
Publication Year :
2021

Abstract

Background A new prolonged-release formulation of potassium citrate and potassium bicarbonate, ADV7103, has been shown to improve metabolic control, palatability, and gastrointestinal safety in patients with distal renal tubular acidosis (dRTA) when compared to standard of care (SoC) treatments. The present work evaluates safety and efficacy of ADV7103 during 24 months. Methods Thirty pediatric and adult patients were included in an open-label extension study after a phase II/III trial. Safety and tolerability were assessed. Plasma bicarbonate and potassium levels, as well as urine parameters, were evaluated over time. Acceptability, adherence, and quality of life were also assessed. The evolution of clinical consequences of dRTA in the cohort was explored. Results There were 104 adverse events (AEs) reported, but only 9 gastrointestinal events observed in five patients (17%) were considered to be related to ADV7103 treatment. There were no AEs leading to treatment discontinuation. Plasma bicarbonate and potassium levels were in the normal ranges at the different visits, respectively, in 69-86% and 83-93% of patients. Overall adherence rates were [greater than or equal to] 75% throughout the whole study in 79% patients. An average improvement of quality of life of 89% was reported at 24 months of study. Conclusions Common AEs concerned metabolism and gastrointestinal disorders; the former being related to the disease. Less than half of the gastrointestinal AEs were related to ADV7103 treatment and they were mostly mild in severity. Metabolic parameters were maintained in the normal ranges in most patients. Patient satisfaction was high and adherence to treatment was good and remained stable. Trial registration number Registered as EudraCT 2013-003828-36 on the 3rd of September 2013. Graphical Abstract<br />Author(s): Aurélia Bertholet-Thomas [sup.1] , Catherine Guittet [sup.2] , Maria A. Manso-Silván [sup.2] , Sophie Joukoff [sup.2] , Victor Navas-Serrano [sup.2] , Véronique Baudouin [sup.3] , Mathilde Cailliez [sup.4] , [...]

Details

Language :
English
ISSN :
0931041X
Volume :
36
Issue :
7
Database :
Gale General OneFile
Journal :
Pediatric Nephrology
Publication Type :
Academic Journal
Accession number :
edsgcl.666293942
Full Text :
https://doi.org/10.1007/s00467-020-04873-0